{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T21:51:59Z","timestamp":1790373119896,"version":"4.1.0"},"reference-count":13,"publisher":"Japanese Society of Internal Medicine","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2018,8,15]]},"DOI":"10.2169\/internalmedicine.0578-17","type":"journal-article","created":{"date-parts":[[2018,3,8]],"date-time":"2018-03-08T17:26:48Z","timestamp":1520530008000},"page":"2395-2398","source":"Crossref","is-referenced-by-count":20,"title":["Paraneoplastic Pemphigus Associated with B-cell Chronic Lymphocytic Leukemia Treated with Ibrutinib and Rituximab"],"prefix":"10.2169","volume":"57","author":[{"given":"Yuta","family":"Ito","sequence":"first","affiliation":[{"name":"Department of Hematology, National Cancer Center Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Makita","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Cancer Center Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko Miyagi","family":"Maeshima","sequence":"additional","affiliation":[{"name":"Department of Pathology, National Cancer Center Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Hatta","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Cancer Center Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomotaka","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Cancer Center Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayako","family":"Yuda","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Cancer Center Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suguru","family":"Fukuhara","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Cancer Center Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Munakata","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Cancer Center Hospital, Japan"},{"name":"Rare Cancer Center, National Cancer Center Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Cancer Center Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai","family":"Maruyama","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Cancer Center Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Izutsu","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Cancer Center Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Anhalt GJ, Kim SC, Stanley JR, et al. Paraneoplastic pemphigus. An autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med 323: 1729-1735, 1990.","DOI":"10.1056\/NEJM199012203232503"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Leger S, Picard D, Ingen-Hounsz-Oro S, et al. Prognostic factors of paraneoplastic pemphigus. Arch Dermatol 148: 1165-1172, 2012.","DOI":"10.1001\/archdermatol.2012.1830"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Frew JW, Murrell DF. Current management strategies in paraneoplastic pemphigus (paraneoplastic autoimmune multiorgan syndrome). Dermatol Clin 29: 607-612, 2011.","DOI":"10.1016\/j.det.2011.06.016"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Wiezorek M, Czernik A. Paraneoplastic pemphigus: a short review. Clin Cosmet Investig Dermatol 9: 291-295, 2016.","DOI":"10.2147\/CCID.S100802"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Joly P, Maho-Vaillent M, Prost-Squarcioni C, et al. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux3): a prospective, multicenter, parallel-group, open-label randomized trial. Lancet 389: 2031-2040, 2017.","DOI":"10.1016\/S0140-6736(17)30070-3"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Lee A, Sandhu S, Imalay-Gillespie L, Mulligan S, Shumack S. Successful use of Bruton&apos;s kinase inhibitor, ibrutinib, to control paraneoplastic pemphigus in a patient with paraneoplastic autoimmune multiorgan syndrome and chronic lymphocytic leukemia. Australas J Dermatol 58: e240-e242, 2017.","DOI":"10.1111\/ajd.12615"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Tobinai K, Ogura M, Ishizawa K, et al. Safety and tolerability of ibrutinib monotherapy in Japanese patients with relapsed\/refractory B cell malignancies. Int J Hematol 103: 86-94, 2016.","DOI":"10.1007\/s12185-015-1900-3"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Byrd JC, Brown JR, O&apos;Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 371: 213-223, 2014.","DOI":"10.1056\/NEJMoa1400376"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Fischer K, Cramer P, Busch R, et al. Bendamustine combined with rituximab in patients with relapsed and\/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 29: 3559-3566, 2011.","DOI":"10.1200\/JCO.2010.33.8061"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Eichhorst B, Robak T, Montserrat E, et al. Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 26 (Suppl 5): v78-v84, 2015.","DOI":"10.1093\/annonc\/mdv303"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Burger JA, Keating MJ, Wierda WG, et al. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm phase 2 study. Lancet Oncol 15: 1090-1099, 2014.","DOI":"10.1016\/S1470-2045(14)70335-3"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Seymour JF, Ma S, Brander DM, et al. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. Lancet Oncol 18: 230-240, 2017.","DOI":"10.1016\/S1470-2045(17)30012-8"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Heinzmann M, Itin P, Wernli M, Borradori L, Bargetzi MJ. Successful treatment of paraneoplastic pemphigus in follicular NHL with rituximab: report of a case and review of treatment for paraneoplastic pemphigus in NHL and CLL. Am J Hematol 66: 142-144, 2001.","DOI":"10.1002\/1096-8652(200102)66:2<142::AID-AJH1032>3.0.CO;2-0"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/57\/16\/57_0578-17\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,8,18]],"date-time":"2018-08-18T00:48:24Z","timestamp":1534553304000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/57\/16\/57_0578-17\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,15]]},"references-count":13,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.0578-17","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,15]]}}}